
Opinion|Videos|July 23, 2024
NCCN Recommendations by PD-L1 Expression Level
A panel of experts discuss how the NCCN guideline recommendations differ for patients with and without PD-L1 expression.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the NCCN guideline recommendations differ for patients without PD-L1 expression (<1%) compared with those with low (1%-49%) or high (≥50%) expression?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5